PDCD1 and neoplasm: To address these issues, we turned our attention to several other immune checkpoints than CTLA-4 and PD-1/PD-L1 that may be useful for treatment, and we compared the differences in the tumor immune microenvironment between primary and metastatic lesions in patients with NSCLC brain metastases to find therapeutic methods that benefit the patients.